The Valley Desk

Clinical trial reportJournal of clinical oncology : official journal of the American Society of Clinical OncologyPublished

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

11 of 49 authors shown in byline order.

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Clinical trial report
Venue
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Acrylamides; Morpholines; Pyrazoles; Pyrimidines; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Bispecific; Injections, Subcutaneous; Mutation; Adult
PubMed ID
38857463
PubMed Central ID
PMC11469630
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal